Unibest

Pharmaceutical intermediates

atrasentan Intermediates

2 pharmaceutical intermediates for atrasentan. Indication: Proteinuria; Immunoglobulin A Nephropathy (IgA Nephropathy).

提交项目All intermediates

About atrasentan

Originator
Abbvie
Indication
Proteinuria; Immunoglobulin A Nephropathy (IgA Nephropathy)
Approved Date
04/02/2025
NCE Patent
04/02/2030
DS/DP
08/22/2028

Available intermediates

2 intermediates currently listed for atrasentan. Request specifications, documentation or a quotation for any item below.

atrasentan intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
ethyl trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)pyrrolidine-3-carboxylate178739-07-6//
ethyl (2R,3R,4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)pyrrolidine-3-carboxylate (S)-(+) mandelate195529-63-6//

Other programs under A

AbemaciclibAbrocitinibAcalabrutinibAdagrasibAfatinibAfoxolanerAlectinib HydrochlorideAlfacalcidol

Building toward atrasentan?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →